



15th December 2008

ASX RELEASE

US PRESS RELEASE REGARDING INNOVATION SHOOT OUT

ImpediMed attaches herewith a press release done in the USA regarding its place as a finalist in the 2009 Innovation Shootout.

This was initially announced to ASX on 14th November 2008.

ENDS

For further information contact:

Greg Brown

Impedimed CEO

+61-7-3860-3700

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed had the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients. For more information, visit. www.impedimed.com.

For personal use only

FOR IMMEDIATE RELEASE

Press Contact:
Dan Brown
Mulberry Marketing
415/439-8357 (office)
415/420-7880 (mobile)
dbrown@mulberrymc.com

**Medical Technology Company ImpediMed Named Finalist for 2009
Innovation Shootout**

*~Company will participate in two rounds of competition in Los Angeles and
Silicon Valley~*

SAN FRANCISCO – December 12, 2008 – Leading innovator of medical devices, ImpediMed Ltd., has been named a finalist in the 2009 Innovation Shootout, taking place in January in Los Angeles and Silicon Valley.

ImpediMed Limited is a world leader in the development and distribution of medical devices using Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of human disorders and diseases. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, radiation oncologists and therapists to clinically assess secondary unilateral lymphedema of the arm in female breast cancer survivors. Pre-operative assessment in combination with periodic surveillance can assist medical professionals to detect lymphedema before the onset of visible symptoms, and potentially before the condition progresses to irreversible forms. Irreversible lymphedema can become a lifelong management issue for patients and can significantly impair their quality of life.

ImpediMed has the first and only US FDA cleared medical device for the clinical assessment, by health care providers, of secondary lymphedema of the arm in female breast cancer patients.

ImpediMed's L-Dex technology utilizes the characteristics of frequency dependent current flow to quantify changes in extra-cellular fluid in the patient's limb. These changes can assist the surgeon and oncologist in clinically assessing patients for the early signs of lymphedema. L-Dex technology is specific for extra-cellular fluid. As fluid accumulates, L-Dex values increase on the L-Dex scale. The device provides an immediate result and is provided with software for tracking changes in patient's L-Dex values over time.

Lymphedema is a condition that can cause significant swelling of the upper and lower extremities due to the build-up of excess lymph fluid. This can occur when the lymphatic system, which is responsible for draining excess fluid from the body, is damaged or altered. In breast cancer patients, this can occur after surgery, such as removal or biopsy of the lymph nodes, and/or radiation therapy. It is estimated that between six and 40 percent of patients with breast

For personal use only

cancer develop lymphedema. For some cancer survivors and others at risk, lymphedema can occur years after initial primary treatment, and develop into a condition that can have a serious impact on the overall health and quality of life.

"The increasing mantra from US experts in the area of managing breast cancer patients is the recognition that pre-operative assessment, early detection and treatment of lymphedema is the best way to prevent and manage this important medical condition," said Greg Brown, ImpediMed's CEO. "ImpediMed's L-Dex family of devices has the potential to aid in this critical role in the pre-operative assessment and management of lymphedema in female breast cancer patients".

ImpediMed's technology was developed by The Queensland University of Technology and The University of Queensland. The company was formed in late 1999 by The University of Queensland in order to commercialize this technology.

The Innovation Shootout is sponsored by the six State Governments of Australia, each of which chooses a local company that has developed a cutting edge technological advancement as its state finalist. Finalists will give presentations about their companies on January 13th during the Innovation Fast Pitch, taking place at the Business Technology Center, run by the Community Development Commission of the County of Los Angeles. They will then travel to the Bay Area to participate in the Innovation Shootout on January 15th at the Quadras Conference Center in Menlo Park. The winner will be selected by a panel of judges including technology experts, members of the media, and venture capitalists.

"Queensland has always been a leader in the development of new biomedical technologies," said the Honorable Peter Beattie, Queensland's Commissioner for the Americas. "Impedimed is one company that is leading the way in making life better for people around the world who are suffering from harmful and debilitating illnesses."

Members of the media wishing to secure tickets for this year's Australian Innovation Fast Pitch on January 13th in Los Angeles, or the Australian Innovation Shoot Out on January 15th in Silicon Valley should contact Dan Brown of Mulberry Marketing at 415-439-8357 or dbrown@mulberrymc.com. All Innovation Shoot Out events are invitation only, members of the general public should contact Louis Matthews from Advance Louis@advance.org to express their interest in attending these events.

Additionally, journalists interested in speaking to ImpediMed representatives, or doctors using ImpediMed products, should contact Dan Brown at 415-439-8357 or dbrown@mulberrymc.com.

#

About ImpediMed

ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies to aid medical providers in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed's primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists to clinically assess patients for the potential onset of secondary lymphedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may help prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals clinically assess secondary lymphedema of the arm in female breast cancer patients. For more information, visit www.impedimed.com.

The L-Dex scale is not intended to diagnose or predict lymphedema of an extremity.